Sector News

Impax Labs names industry veteran Paul Bisaro as CEO

March 28, 2017
Life sciences

Impax Laboratories Inc, which is said to be conducting a strategic review, named former Allergan Plc executive and industry veteran Paul Bisaro as its chief executive, sending the drugmaker’s shares soaring as much as 38 percent.

The past year has seen mounting pressure on generic drugmakers, as speedier approvals of generic products by U.S. regulators ratchet up competition in the sector, squeezing smaller players such as Impax, that lack bargaining power.

Impax has asked investment bank Morgan Stanley to help it conduct a strategic review, people familiar with the matter told Reuters earlier this month.

Bisaro, 56, was largely behind transforming a much smaller generic drugmaker Watson Pharmaceuticals, at a couple of billion dollars in market cap, into the current version of Allergan with a market valuation of about $80 billion.

Given some of Impax’s near-term challenges and Bisaro’s still relatively young age, Leerink analysts believe he is committing to a process that may not be short-term.

However, the hire and the Reuters report suggest Impax will be an active acquirer or future M&A target, Leerink said.

Bisaro, whose appointment is effective immediately, succeeds Kevin Buchi, who has served as interim president and chief executive since December.

“Bisaro is one of a handful of experienced generic industry executives we have gotten to know over the past 18 years that has demonstrated a solid track record of execution,” BTIG analysts said, raising their price target to $16 from $13.

Impax’s shares were up 38.65 percent at $12.83, set for their best day in more than 8 years.

By Ankur Banerjee

Source: Reuters

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”